Piperidine Derivatives Targeting Human CGRP Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with excessive calcitonin gene-related peptide (CGRP) receptor activation, such as migraine headaches, lack effective and selective options that avoid cardiovascular liabilities, and existing CGRP antagonists show species-specific differences in efficacy.
Innovation Solution
Development of novel CGRP antagonist compounds, including specific pharmaceutical compositions and methods for their use, which inhibit CGRP receptors with improved binding affinity, selectivity, and safety profiles, utilizing specific structural formulas and synthesis methods to target human CGRP receptors effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CGRP antagonists are used to treat migraine headaches, then CGRP receptor activation is inhibited, but species-specific differences reduce efficacy in human patients
Solution Approach 1:
The patent applies local quality by designing the compound structure to specifically interact with human CGRP receptor characteristics. The piperidine derivative structure with specific substituents (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12) is optimized to match the binding pocket of the human CGRP1 receptor, which contains the distinctive Trp74 residue. This localized structural optimization ensures high affinity and selectivity for the human receptor while maintaining the general CGRP antagonism mechanism.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical parameters of the CGRP antagonist compounds. The general formula I structure allows for multiple substituent variations at different positions (R1-R12), enabling optimization of binding affinity, selectivity, and pharmacokinetic properties. This parameter optimization resolves the species-specific efficacy issue by tuning the molecular characteristics to match human receptor requirements.
2Reliability
If non-selective 5-HT1B/1D agonists (triptans) are used to treat migraine, then headache relief is achieved, but cardiovascular liabilities occur
Solution Approach 1:
The patent applies the taking out principle by extracting and isolating the therapeutic effect (CGRP receptor antagonism) from the harmful effects (cardiovascular vasoconstriction) associated with triptans. Instead of using non-selective 5-HT1B/1D agonists that cause both headache relief and cardiovascular side effects, the invention selectively targets only the CGRP1 receptor pathway responsible for migraine pathophysiology. This selective targeting removes the cardiovascular liabilities while preserving the analgesic benefit.
Solution Approach 2:
The patent uses CGRP receptor antagonism as an intermediary mechanism to achieve headache relief without direct vasoconstriction. Rather than activating 5-HT1B/1D receptors that directly constrict blood vessels, the invention blocks CGRP-mediated vasodilation and neurogenic inflammation pathways. This intermediary approach provides indirect headache relief by normalizing CGRP levels and blocking its pro-migraine effects, avoiding direct cardiovascular stimulation.
3Reliability
If CGRP receptor antagonists are developed with high binding affinity, then selectivity for human receptors improves, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex binding interaction into modular components represented by the general formula I structure. The core piperidine scaffold is segmented into multiple positions (R1-R12) that can be independently optimized. This modular approach allows systematic improvement of binding affinity through sequential optimization of individual substituents rather than attempting to design the entire complex molecule at once, reducing the perceived complexity while achieving high affinity.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The disclosure generally relates to the novel compounds of formula I, including their salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD). (I)